The cluster suggests institutional de-risking ahead of potential catalysts or continued cash burn. Monitor for further insider selling or a capital raise, as the selling pressure from large holders like Citadel and Morgan Stanley may persist. The quant buying is small and likely algorithmic, not thesis-driven.
FATE drugs
FATE drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 11 $1.97entry
- T+1 · 5mo ago +4.57%α +4.03% · $2.06
- T+5 · 5mo ago −0.51%α −0.94% · $1.96
- T+20 · 4mo ago +57.87%α +55.98% · $3.11
- T+60 · 2mo ago +25.89%α +21.49% · $2.48
How similar events traded
Executive Summary
FATE Therapeutics saw a bearish institutional cluster in Q3 2025, with 5 sellers (including Citadel near-exiting a $5.1M position) overwhelming 2 quant buyers (RenTech and Two Sigma doubling small positions). Net selling of ~$6M signals fading conviction among major holders, consistent with the stock's small $218M market cap and ongoing sector headwinds.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$3.3M
▲ Buyers (2)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| RenTech | DOUBLED | +488.7% | $1.6M | $1.4M |
| Two Sigma | DOUBLED | +294.4% | $1.1M | $879.0K |
▼ Sellers (5)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Citadel | NEAR_EXIT | -81.9% | $5.1M | -$4.1M |
| Morgan Stanley | TRIM | -61.8% | $2.7M | -$1.6M |
| UBS | TRIM | -67.3% | $1.1M | -$681.6K |
| Barclays | TRIM | -53.5% | $507.00 | $265.0K |
| Fidelity | TRIM | -69.2% | $38.0K | -$24.9K |
Key Facts
- 5 institutional sellers vs 2 buyers in Q3 2025
- Citadel reduced 81.9% of its position, selling ~$4.1M worth
- RenTech and Two Sigma doubled small positions but combined buying was only $2.2M
- Net institutional outflow of ~$6M, dominated by passive/quant trimming
- FATE market cap is $218M; the cluster represents ~2.8% of float
Financial Impact
Net institutional selling of approximately $6.0M, with Citadel alone accounting for $4.1M of that. Buyers added $2.2M, but sellers reduced $6.0M.
Risk Factors
- Further institutional selling could pressure the stock given the small float
- Cash burn and lack of near-term revenue catalysts may drive additional exits
- Quant buying is low-conviction and may reverse quickly
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-FATE-2025-Q3 |
Track record
21 reports on FATE
3 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +30.25% at T+5 after the Nov 5, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 13, 20264d ago EFFECT Bearish 5/10 Entry $1.28 settles Nov 20
- Nov 12, 20264d ago 424B5 Bearish 4/10 Entry $1.28 settles Nov 20
- Nov 9, 20267d ago SC 13D/A Neutral 2/10 Entry $1.77 settles Nov 17
- Nov 5, 202611d ago S-3 Neutral 3/10 Entry $1.84 to $1.28 ▼ −30.25% −32.84% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $1.84 to $1.28 ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $1.84 to $1.28 ▲ +30.25% +32.84% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $1.85 to $1.34 ▼ −27.57% −30.86% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $2.09 to $1.61 ▼ −23.21% −22.29% vs SPY
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $2.04 to $1.77 ▼ −13.24% −12.65% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers